Galecto, Inc. has announced the pricing of its underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, totaling approximately $275 million. The offering is expected to close on February 12, 2026, with Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities acting as joint book-running managers. Galecto’s pipeline focuses on developing antibody therapeutics for hematological cancers, including myeloproliferative neoplasms and acute myeloid leukemia. The company’s forward-looking statements emphasize the potential risks and uncertainties associated with the offering and future developments.

For more information, contact Galecto, Inc. via media liaison Lia Dangelico at [email protected] or investor contact Brian Ritchie at [email protected].

Read more at GlobeNewswire: Galecto Announces Pricing of $275 Million Underwritten